Advanced searches left 3/3

Rabies Vaccine - Europe PMC

Summarized by Plex Scholar
Last Updated: 16 July 2022

* If you want to update the article please login/register

Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.

We previously reported that pre-exposure prophylaxis with PVRV-NG had a safe safety profile and was immunogenically non-inferior to the approved purified Vero cell rabies vaccine in adults. Here, we compared PrEP with PVRV-NG to the approved human diploid cell vaccine in healthy adults. On days 0, 28, 42, and 42, as well as Months 6, 12, and 14 days, Rabies virus neutralizing antibodies were tested. PVRV-NG was non-inferior to HDCV on day 42, and the first primary goal was achieved; seroconversion was seen for 98. 3% of PVRV-NG recipients and 99. 1% of HDCV viewers; PVRV-NG was non-inferior to HDCV on day 42. The RVNA geometric mean titres tended to be higher for HDCV than PVRV-NG primary vaccine recipients. 99. 6% and 100% of participants in the PVRV-NG and HDCV groups, respectively, experienced seroconversion in both vaccine groups in a comparative study using alternative criteria for seroconversion.

Source link: https://europepmc.org/article/MED/35778281


Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.

After post-exposure in China, Aim To determine the safety and immunogenicity of rabies vaccine for human use. Both Essen and Zagreb regimens displayed excellent immunogenicity, with no significant change in systemic and local celebrations after PEP, but there was also a high number of local and systemic events after PEP under the Zagreb regime. Conclusion For the Chinese people, rabies vaccination after PEP has been highly effective and safe for preventing human rabies. The Zagreb regimen was also comparable to the Essen regimen in terms of rabies prophylaxis with an acceptable safety record, according to the report.

Source link: https://europepmc.org/article/MED/35750539


Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX.

Background Information The first and only effective rabies reservoir for humans, as well as in humans, is a mass vaccination of dogs as a vital rabies reservoir. Dog vaccination rates in several developing countries are still dangerously poor due to economic challenges and a high turnover in dog populations. Compared to the parental CR cell line, the CR. pIX was previously shown to raise heat shock responses and supported marginally higher infectious titers. Both cell lines allowed replication of rabies virus even in absence of recombinant IGF, the only non-complex component of the chemically defined medium that was developed for the two cell lines. According to the NIH study, the potency of inactivated rabies virus harvest was 3. 5 IU/ml. Conclusion This research shows that a rabies vaccine for animal vaccination can be manufactured quickly in the AGE1. CR. pIX suspension cell line in a scalable process in chemically defined medium.

Source link: https://europepmc.org/article/MED/35715843

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions